Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities

References

• GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide 2012. International Agency for Research on Cancer (IARC), 2012. Available at: http://globocan.iarc.fr/ [Last accessed 6 May 2014]
   Google Scholar
• Cancer Facts & Figures 2014. American Cancer Society, 2014. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index [Last accessed 31 March 2014]
   Google Scholar
• SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute, 2011. Available at: http://seer.cancer.gov/statfacts/html/prost.html [Last accessed 31 March 2014]
   Google Scholar
• Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012;2012:327253. doi: 10.1155/2012/327253
   PubMedGoogle Scholar
• Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol 2010;17(Suppl 2):S72-9
   PubMed Web of Science ®Google Scholar
• Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol 2013;24:31-8
   PubMed Web of Science ®Google Scholar
• Zytiga® (abiraterone acetate) Package Insert. Centocor Ortho Biotech Inc., 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf [Last accessed 4 April 2014]
   Google Scholar
• Waller D. How VA hospitals became the best. Time 2006;168:36-7
   PubMedGoogle Scholar
• VA Information Resource Center. VIReC Research User Guide: VHA Decision Support System Clinical National Data Extracts, 2nd edn. US Department of Veterans Affairs, 2009. Available at: http://www.virec.research.va.gov/References/RUG/RUG-DSS-2nd-Ed-er.pdf [Last accessed 20 April 2014]
   Google Scholar
• VA Information Resource Center. VIReC The Researcher’s Guide to VA data. Medical SAS datasets. US Department of Veterans Affairs, 2014. Available at: http://www.virec.research.va.gov/MedSAS/Overview.htm [Last accessed 20 April 2014]
   Google Scholar
• VA Information Resource Center. Medical SAS® Inpatient Dataset FY2009: VIReC Research User Guide. Hines, IL: U.S. Dept. of Veterans Affairs, Health Services Research and Development Service, VA Information Resource Center, Feb 2011. Available at: http://www.virec.research.va.gov/DataSourcesName/Medical-SAS-Datasets/MedSAS-Inpt-RUG/MedSAS-RUG-Inpt.htm [Last accessed 2 September 2014]
   Google Scholar
• Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13:351-61
   PubMedGoogle Scholar
• Schäcke H, Döcke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
   PubMed Web of Science ®Google Scholar
• Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart 2004;90:859-65
   PubMed Web of Science ®Google Scholar
• Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010;43:753-68
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. The Consumer Price Index. United States Department of Labor, 2014. Available at: http://www.bls.gov/cpi/ [Last accessed 5 May 2014]
   Google Scholar
• Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234-40
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
   PubMed Web of Science ®Google Scholar
• Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
   PubMed Web of Science ®Google Scholar
• Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
   PubMed Web of Science ®Google Scholar
• Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One 2013;8:e64275
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Kizer KW. The VA health care system: an unrecognized national safety net. Health Aff (Millwood) 1997;16:200-4
   PubMed Web of Science ®Google Scholar
• Berglund A, Garmo H, Tishelman C, et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011;185:833-9
   PubMed Web of Science ®Google Scholar
• Houterman S, Janssen-Heijnen ML, Hendrikx AJ, et al. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. Crit Rev Oncol Hematol 2006;58:60-7
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Alibhai SM, Tomlinson G, et al. Continued undertreatment of older men with localized prostate cancer. Urology 2003;62:860-5
   PubMed Web of Science ®Google Scholar
• Hall HI, Satariano WA, Thompson T, et al. Initial treatment for prostate carcinoma in relation to comorbidity and symptoms. Cancer 2002;95:2308-15
   PubMed Web of Science ®Google Scholar
• Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001;93:1864-71
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Pharm 2014;20:477-84
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Baskin-Bey ES, Watson M, et al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol 2013;13:58
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin Ther 2000;22:452-69
   PubMed Web of Science ®Google Scholar